| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing
|
Deloughery, Thomas G.
|
|
|
|
4 |
p.
|
artikel
|
| 2 |
A case of congenital prothrombin deficiency with two concurrent mutations in the prothrombin gene
|
Mansory, Eman M.
|
|
|
|
4 |
p.
|
artikel
|
| 3 |
A comprehensive targeted next‐generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia
|
Johnson, Ben
|
|
|
|
4 |
p. 640-652
|
artikel
|
| 4 |
Adrenaline enhances in vitro platelet activation and aggregation in blood samples from ticagrelor‐treated patients
|
Singh, Sukhi
|
|
|
|
4 |
p. 718-725
|
artikel
|
| 5 |
Advanced practice provider–led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilization
|
Frank, Cassiopeia
|
|
|
|
4 |
p.
|
artikel
|
| 6 |
Agreement of aptamer proteomics with standard methods for measuring venous thrombosis biomarkers
|
Faquih, Tariq
|
|
|
|
4 |
p.
|
artikel
|
| 7 |
Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells
|
Schillemans, Maaike
|
|
|
|
4 |
p. 718-732
|
artikel
|
| 8 |
A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding
|
Jaspers, Tessa
|
|
|
|
4 |
p.
|
artikel
|
| 9 |
A multicenter study to evaluate automated platelet aggregometry on Sysmex CS‐series coagulation analyzers—preliminary findings
|
Platton, Sean
|
|
|
|
4 |
p. 778-789
|
artikel
|
| 10 |
Analysis of procoagulant phosphatidylserine‐exposing platelets by imaging flow cytometry
|
Reddy, Emily C.
|
|
|
|
4 |
p. 736-750
|
artikel
|
| 11 |
A novel association between platelet filamin A and soluble N-ethylmaleimide sensitive factor attachment proteins regulates granule secretion
|
Golla, Kalyan
|
|
|
|
4 |
p.
|
artikel
|
| 12 |
Anticoagulants in frail elderly patients with atrial fibrillation: a delicate balance
|
Trinks-Roerdink, Emmy M.
|
|
|
|
4 |
p.
|
artikel
|
| 13 |
Anti–factor Xa activity assays of direct‐acting oral anticoagulants during clinical care: An observational study
|
Sukumar, Smrithi
|
|
|
|
4 |
p.
|
artikel
|
| 14 |
Antithrombin-lowering in hemophilia: a closer look at fitusiran
|
Young, Guy
|
|
|
|
4 |
p.
|
artikel
|
| 15 |
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
|
Mavromanoli, Anna C.
|
|
|
|
4 |
p.
|
artikel
|
| 16 |
Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
|
Sattler, Laurent
|
|
|
|
4 |
p.
|
artikel
|
| 17 |
Are outpatient anticoagulation management services the wave of the future (again)?
|
Samuelson Bannow, Bethany
|
|
|
|
4 |
p.
|
artikel
|
| 18 |
Are women equal? Considering impact of therapeutic abortion bans on science
|
Cushman, Mary
|
|
|
|
4 |
p.
|
artikel
|
| 19 |
Aspirin at 120: Retiring, recombining, or repurposing?
|
Patrono, Carlo
|
|
|
|
4 |
p.
|
artikel
|
| 20 |
Assessing quality of life after pulmonary embolism: Comparing results from the PEmb‐QoL with semistructured interviews
|
Hernandez‐Nino, Jackeline
|
|
|
|
4 |
p.
|
artikel
|
| 21 |
Atrial fibrillation in patients with end‐stage renal disease on hemodialysis: Magnitude of the problem and new approach to oral anticoagulation
|
Königsbrügge, Oliver
|
|
|
|
4 |
p. 578-588
|
artikel
|
| 22 |
Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and meta‐analysis
|
Friis Berntsen, Christopher
|
|
|
|
4 |
p.
|
artikel
|
| 23 |
Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
|
Shima, Midori
|
|
|
|
4 |
p. 446-454
|
artikel
|
| 24 |
Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
|
Hermans, Cedric
|
|
|
|
4 |
p.
|
artikel
|
| 25 |
Bleeding disorders and postpartum hemorrhage by mode of delivery: a retrospective cohort study
|
Niu, Bonnie
|
|
|
|
4 |
p.
|
artikel
|
| 26 |
Blood coagulation test abnormalities in trauma patients detected by sonorheometry: a retrospective cohort study
|
Duclos, Gary
|
|
|
|
4 |
p.
|
artikel
|
| 27 |
Blood platelet research in autism spectrum disorders: In search of biomarkers
|
Padmakumar, Manisha
|
|
|
|
4 |
p. 566-577
|
artikel
|
| 28 |
Blood platelets: Circulating mirrors of neurons?
|
Canobbio, Ilaria
|
|
|
|
4 |
p. 564-565
|
artikel
|
| 29 |
Cancer‐associated thrombosis: The search for the holy grail continues
|
Ünlü, Betül
|
|
|
|
4 |
p. 622-629
|
artikel
|
| 30 |
Cancer‐associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study
|
Sharman Moser, Sarah
|
|
|
|
4 |
p.
|
artikel
|
| 31 |
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
|
Bauersachs, Rupert
|
|
|
|
4 |
p. 532-549
|
artikel
|
| 32 |
Cerebral sinovenous thrombosis in pediatric hemolytic uremic syndrome
|
Wyatt, Kirk D.
|
|
|
|
4 |
p. 659-665
|
artikel
|
| 33 |
Characterization of a transgenic mouse model of chronic conditional platelet depletion
|
Wuescher, Leah M.
|
|
|
|
4 |
p. 704-712
|
artikel
|
| 34 |
Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research
|
Dover, Saunya
|
|
|
|
4 |
p. 652-658
|
artikel
|
| 35 |
Coagulation biomarkers for ischemic stroke
|
Barakzie, Aarazo
|
|
|
|
4 |
p.
|
artikel
|
| 36 |
Coagulation test understanding and ordering by medical trainees: Novel teaching approach
|
Gabarin, Nadia
|
|
|
|
4 |
p.
|
artikel
|
| 37 |
Comparison is not reason: Pitfalls in reporting thrombin generation results in anticoagulated patients
|
Douxfils, Jonathan
|
|
|
|
4 |
p.
|
artikel
|
| 38 |
Comparison of antithrombin‐dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots
|
Salta, Stella
|
|
|
|
4 |
p. 696-707
|
artikel
|
| 39 |
Comparison of novel thrombin generation methods with established techniques is mandatory
|
Helin, Tuukka
|
|
|
|
4 |
p.
|
artikel
|
| 40 |
Comparison of the coagulopathies associated with COVID‐19 and sepsis
|
Campbell, Robert A.
|
|
|
|
4 |
p.
|
artikel
|
| 41 |
Considerations for use of direct oral anticoagulants in arterial disease
|
Siegal, Deborah M.
|
|
|
|
4 |
p.
|
artikel
|
| 42 |
Corrigendum
|
|
|
|
|
4 |
p. 772-774
|
artikel
|
| 43 |
Corrigendum
|
|
|
|
|
4 |
p. 771
|
artikel
|
| 44 |
Corrigendum to ‘Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis’ [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]
|
Pipe, Steven W.
|
|
|
|
4 |
p.
|
artikel
|
| 45 |
Corrigendum to Performance of standard dose enoxaparin in preventing pregnancy‐ Associated venous thromboembolism
|
|
|
|
|
4 |
p. 666
|
artikel
|
| 46 |
COVID‐19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance
|
Cannegieter, Suzanne C.
|
|
|
|
4 |
p. 439-445
|
artikel
|
| 47 |
COVID‐19 hypothesis: Activated protein C for therapy of virus‐induced pathologic thromboinflammation
|
Griffin, John H.
|
|
|
|
4 |
p. 506-509
|
artikel
|
| 48 |
D‐dimer testing in clinical practice in the era of COVID‐19
|
Auditeau, Claire
|
|
|
|
4 |
p.
|
artikel
|
| 49 |
Deep learning detects and visualizes bleeding events in electronic health records
|
Pedersen, Jannik S.
|
|
|
|
4 |
p.
|
artikel
|
| 50 |
Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes
|
Brunton, Nichole E.
|
|
|
|
4 |
p.
|
artikel
|
| 51 |
Detection of tissue factor–positive extracellular vesicles using the ExoView R100 system
|
Price, Joshua M.J.
|
|
|
|
4 |
p.
|
artikel
|
| 52 |
Developing and optimizing a computable phenotype for incident venous thromboembolism in a longitudinal cohort of patients with cancer
|
Li, Ang
|
|
|
|
4 |
p.
|
artikel
|
| 53 |
Development of a computable phenotype using electronic health records for venous thromboembolism in medical inpatients: the Medical Inpatient Thrombosis and Hemostasis study
|
Thomas, Ryan M.
|
|
|
|
4 |
p.
|
artikel
|
| 54 |
Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device‐induced acquired von Willebrand syndrome
|
Deconinck, Shannen
|
|
|
|
4 |
p. 762-766
|
artikel
|
| 55 |
Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system
|
Pfrepper, Christian
|
|
|
|
4 |
p. 619-627
|
artikel
|
| 56 |
Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017
|
Lutsey, Pamela L.
|
|
|
|
4 |
p. 668-673
|
artikel
|
| 57 |
Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
|
Moik, Florian
|
|
|
|
4 |
p. 550-561
|
artikel
|
| 58 |
Disruptive technology and hemophilia care: The multiple impacts of emicizumab
|
Hermans, Cedric
|
|
|
|
4 |
p.
|
artikel
|
| 59 |
Diversity and inclusion in a new medical journal: Advancing science in the 21st century
|
Cushman, Mary
|
|
|
|
4 |
p. 620-621
|
artikel
|
| 60 |
Does publication bias explain the divergent findings on menopausal hormone therapy and cardioprotection in the literature?
|
El Khoudary, Samar R.
|
|
|
|
4 |
p.
|
artikel
|
| 61 |
Economic impact of a rapid, on‐demand ADAMTS‐13 activity assay for the diagnosis of thrombotic thrombocytopenic purpura
|
White, Alicia
|
|
|
|
4 |
p.
|
artikel
|
| 62 |
Editorial Board
|
|
|
|
|
4 |
p.
|
artikel
|
| 63 |
Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer
|
Kasthuri, Raj S.
|
|
|
|
4 |
p. 636-643
|
artikel
|
| 64 |
Effect of lower‐leg trauma and knee arthroscopy on procoagulant phospholipid‐dependent activity
|
Touw, Carolina E.
|
|
|
|
4 |
p.
|
artikel
|
| 65 |
Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease
|
Brown, Megan C.
|
|
|
|
4 |
p.
|
artikel
|
| 66 |
Emergence of institutional antithrombotic protocols for coronavirus 2019
|
Cohoon, Kevin P.
|
|
|
|
4 |
p. 510-517
|
artikel
|
| 67 |
Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate
|
Bavalia, Roisin
|
|
|
|
4 |
p. 569-581
|
artikel
|
| 68 |
Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
|
Trujillo‐Santos, Javier
|
|
|
|
4 |
p.
|
artikel
|
| 69 |
Erratum
|
|
|
|
|
4 |
p. 770
|
artikel
|
| 70 |
Evaluating hemostatic thresholds for neuraxial anesthesia in adults with hemorrhagic disorders and tendencies: A scoping review
|
Peterson, Wynn
|
|
|
|
4 |
p.
|
artikel
|
| 71 |
Evaluation of a semi‐automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers
|
Bowyer, Annette E.
|
|
|
|
4 |
p. 790-799
|
artikel
|
| 72 |
Evaluation of point‐of‐care International Normalized Ratio in sickle cell disease
|
Rahman, Syeda
|
|
|
|
4 |
p.
|
artikel
|
| 73 |
Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients
|
Pabinger, Ingrid
|
|
|
|
4 |
p.
|
artikel
|
| 74 |
Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
|
Levy-Mendelovich, Sarina
|
|
|
|
4 |
p.
|
artikel
|
| 75 |
Factor XII – What's important but not commonly thought about
|
Schmaier, Alvin H.
|
|
|
|
4 |
p. 599-606
|
artikel
|
| 76 |
Fatigue after initiating rivaroxaban for venous thromboembolism
|
Karlsvik, Tina Margrethe
|
|
|
|
4 |
p. 582-585
|
artikel
|
| 77 |
F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China
|
Sun, Jie
|
|
|
|
4 |
p.
|
artikel
|
| 78 |
Fibrinolysis and bleeding of unknown cause
|
Mehic, Dino
|
|
|
|
4 |
p.
|
artikel
|
| 79 |
Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review
|
Barrett, Christopher D.
|
|
|
|
4 |
p. 524-531
|
artikel
|
| 80 |
Genomics and transcriptomics of megakaryocytes and platelets: Implications for health and disease
|
Fisher, Marlie H.
|
|
|
|
4 |
p. 630-639
|
artikel
|
| 81 |
GPIbα is the driving force of hepatic thrombopoietin generation
|
Karakas, Danielle
|
|
|
|
4 |
p.
|
artikel
|
| 82 |
Hematologic concerns in extracorporeal membrane oxygenation
|
Sniderman, Jonathan
|
|
|
|
4 |
p. 455-468
|
artikel
|
| 83 |
Hemophilia gene therapy knowledge and perceptions: Results of an international survey
|
Peyvandi, Flora
|
|
|
|
4 |
p. 644-651
|
artikel
|
| 84 |
Hemostasis and tumor immunity
|
Cantrell, Rachel
|
|
|
|
4 |
p.
|
artikel
|
| 85 |
Hemostatic complications associated with ventricular assist devices
|
Hilal, Talal
|
|
|
|
4 |
p. 589-598
|
artikel
|
| 86 |
Hormonal therapies and venous thrombosis: considerations for prevention and management—a reappraisal
|
Douxfils, Jonathan
|
|
|
|
4 |
p.
|
artikel
|
| 87 |
Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias
|
Baldwin, Maureen K.
|
|
|
|
4 |
p.
|
artikel
|
| 88 |
Human platelets release amyloid peptides β1-40 and β1-42 in response to hemostatic, immune, and hypoxic stimuli
|
Wolska, Nina
|
|
|
|
4 |
p.
|
artikel
|
| 89 |
Identification and characterization of novel mutations implicated in congenital fibrinogen disorders
|
Smith, Natalie
|
|
|
|
4 |
p. 800-811
|
artikel
|
| 90 |
Identification of von Willebrand factor D4 domain mutations in patients of Afro‐Caribbean descent: In vitro characterization
|
Dubois, Marie‐Daniéla
|
|
|
|
4 |
p.
|
artikel
|
| 91 |
“If I wasn't a girl”: Experiences of adolescent girls with heavy menstrual bleeding and inherited bleeding disorders
|
Parker, Mackenzie
|
|
|
|
4 |
p.
|
artikel
|
| 92 |
Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress
|
Kahn, Susan R.
|
|
|
|
4 |
p.
|
artikel
|
| 93 |
Immune‐mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure
|
Joseph, Adrien
|
|
|
|
4 |
p.
|
artikel
|
| 94 |
Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding
|
MacLehose, Richard F.
|
|
|
|
4 |
p.
|
artikel
|
| 95 |
Impact of your results: Beyond the relative risk
|
Siegerink, Bob
|
|
|
|
4 |
p. 653-657
|
artikel
|
| 96 |
Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
|
Wong, Pancras C.
|
|
|
|
4 |
p.
|
artikel
|
| 97 |
Increased risk of thrombotic events in cold agglutinin disease: A 10‐year retrospective analysis
|
Broome, Catherine M.
|
|
|
|
4 |
p. 628-635
|
artikel
|
| 98 |
Indeterminate serotonin release assays are associated with a high mortality rate
|
Jindal, Shawn
|
|
|
|
4 |
p.
|
artikel
|
| 99 |
Indoleamine 2,3‐dioxygenase 1 in coronary atherosclerotic plaque enhances tissue factor expression in activated macrophages
|
Watanabe, Yuki
|
|
|
|
4 |
p. 726-735
|
artikel
|
| 100 |
Inherited thrombophilia and portal vein thrombosis in cirrhosis: A systematic review and meta‐analysis
|
Ma, Steven D.
|
|
|
|
4 |
p. 658-667
|
artikel
|
| 101 |
Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants
|
Metze, Michael
|
|
|
|
4 |
p. 610-618
|
artikel
|
| 102 |
Inside-to-outside and back to the future of megakaryopoiesis
|
Di Buduo, Christian Andrea
|
|
|
|
4 |
p.
|
artikel
|
| 103 |
In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus
|
Brummel‐Ziedins, Kathleen E.
|
|
|
|
4 |
p. 708-717
|
artikel
|
| 104 |
ISSUE INFORMATION
|
|
|
|
|
4 |
p. 615-619
|
artikel
|
| 105 |
Issue Information
|
|
|
|
|
4 |
p.
|
artikel
|
| 106 |
ISSUE INFORMATION
|
|
|
|
|
4 |
p. 555-559
|
artikel
|
| 107 |
ISSUE INFORMATION
|
|
|
|
|
4 |
p. 433-437
|
artikel
|
| 108 |
Issue Information
|
|
|
|
|
4 |
p.
|
artikel
|
| 109 |
Issue Information
|
|
|
|
|
4 |
p.
|
artikel
|
| 110 |
Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range?
|
van Miert, Jasper H.A.
|
|
|
|
4 |
p. 604-609
|
artikel
|
| 111 |
Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
|
Persson, Egon
|
|
|
|
4 |
p. 713-717
|
artikel
|
| 112 |
Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
|
Li, Zekun
|
|
|
|
4 |
p. 741-748
|
artikel
|
| 113 |
Management of anticoagulation for cancer‐associated thrombosis in patients with thrombocytopenia: A systematic review
|
Samuelson Bannow, Bethany R.
|
|
|
|
4 |
p. 664-669
|
artikel
|
| 114 |
Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement
|
Held, Nicole
|
|
|
|
4 |
p.
|
artikel
|
| 115 |
Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis
|
Levy, Jerrold H.
|
|
|
|
4 |
p. 562-568
|
artikel
|
| 116 |
Management of therapeutic unfractionated heparin in COVID‐19 patients: A retrospective cohort study
|
Weeks, Lachelle D.
|
|
|
|
4 |
p.
|
artikel
|
| 117 |
Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
|
Scheres, Luuk J.J.
|
|
|
|
4 |
p. 689-695
|
artikel
|
| 118 |
Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)
|
Dover, Saunya
|
|
|
|
4 |
p.
|
artikel
|
| 119 |
Meta‐analysis: Key features, potentials and misunderstandings
|
Dekkers, Olaf M.
|
|
|
|
4 |
p. 658-663
|
artikel
|
| 120 |
Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review
|
Li, Ke Xuan
|
|
|
|
4 |
p.
|
artikel
|
| 121 |
Molecular analysis of vascular gene expression
|
Van der Ent, Martijn A.
|
|
|
|
4 |
p.
|
artikel
|
| 122 |
Multicolor flow cytometry in clinical samples for platelet signaling assessment
|
Garcia, Cedric
|
|
|
|
4 |
p.
|
artikel
|
| 123 |
Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study
|
Murray, Suzanne
|
|
|
|
4 |
p. 626-638
|
artikel
|
| 124 |
No association of low‐dose aspirin with severe COVID‐19 in France: A cohort of 31.1 million people without cardiovascular disease
|
Botton, Jérémie
|
|
|
|
4 |
p.
|
artikel
|
| 125 |
Novel interaction of properdin and coagulation factor XI: Crosstalk between complement and coagulation
|
Heal, Samantha L.
|
|
|
|
4 |
p.
|
artikel
|
| 126 |
Novel mutation in coagulation factor VII (Carmel mutation): Identification and characterization
|
Cassel, Aliza
|
|
|
|
4 |
p.
|
artikel
|
| 127 |
Outcomes in infants with unprovoked venous thromboembolism: A retrospective cohort study
|
Whitworth, Hilary
|
|
|
|
4 |
p.
|
artikel
|
| 128 |
Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set
|
van Balen, Erna C.
|
|
|
|
4 |
p.
|
artikel
|
| 129 |
Patients’ and health care providers’ perspectives on quality of hemophilia care in the Netherlands: a questionnaire and interview study
|
Brands, Martijn R.
|
|
|
|
4 |
p.
|
artikel
|
| 130 |
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study
|
Piran, Siavash
|
|
|
|
4 |
p. 684-688
|
artikel
|
| 131 |
Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
|
Lissitchkov, Toshko
|
|
|
|
4 |
p.
|
artikel
|
| 132 |
Phosphatidylinositol 3‐monophosphate: A novel actor in thrombopoiesis and thrombosis
|
Valet, Colin
|
|
|
|
4 |
p. 491-499
|
artikel
|
| 133 |
Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment
|
Groat, Danielle
|
|
|
|
4 |
p.
|
artikel
|
| 134 |
PIK3R3 is a candidate regulator of platelet count in people of Bangladeshi ancestry
|
Burley, Kate
|
|
|
|
4 |
p.
|
artikel
|
| 135 |
Plasma extracellular vesicle test sample to standardize flow cytometry measurements
|
Bettin, Britta
|
|
|
|
4 |
p.
|
artikel
|
| 136 |
Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease
|
Gibson, Breanne H.Y.
|
|
|
|
4 |
p. 469-480
|
artikel
|
| 137 |
Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome
|
Grosdidier, Charlotte
|
|
|
|
4 |
p. 684-694
|
artikel
|
| 138 |
Platelet CLEC‐2 and lung development
|
Suzuki‐Inoue, Katsue
|
|
|
|
4 |
p. 481-490
|
artikel
|
| 139 |
Platelet preparation for function testing in the laboratory and clinic: Historical and practical aspects
|
Hechler, Béatrice
|
|
|
|
4 |
p. 615-625
|
artikel
|
| 140 |
Platelet versus plasma CXCL14, coronary artery disease, and clinical outcomes
|
Schories, Christoph
|
|
|
|
4 |
p.
|
artikel
|
| 141 |
Poststroke venous thromboembolism and neutrophil activation: an illustrated review
|
Dhanesha, Nirav
|
|
|
|
4 |
p.
|
artikel
|
| 142 |
Post‐thrombotic syndrome in children: Measurement properties of CAPTSure, a new diagnostic tool
|
Avila, Maria Laura
|
|
|
|
4 |
p. 652-657
|
artikel
|
| 143 |
Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice
|
Vries, Minka J.
|
|
|
|
4 |
p. 767-777
|
artikel
|
| 144 |
Preventing swarm detection in extracellular vesicle flow cytometry: a clinically applicable procedure
|
Buntsma, Naomi C.
|
|
|
|
4 |
p.
|
artikel
|
| 145 |
Prolonged APTT of unknown etiology: A systematic evaluation of causes and laboratory resource use in an outpatient hemostasis academic unit
|
Barbosa, Ayla Cristina Nóbrega
|
|
|
|
4 |
p. 749-757
|
artikel
|
| 146 |
Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review
|
Evans, Christina R.
|
|
|
|
4 |
p.
|
artikel
|
| 147 |
Protein S K196E mutation reduces its cofactor activity for APC but not for TFPI
|
Maruyama, Keiko
|
|
|
|
4 |
p. 751-756
|
artikel
|
| 148 |
Publishing in the COVID Era
|
Cushman, Mary
|
|
|
|
4 |
p. 438
|
artikel
|
| 149 |
Pulmonary embolism and deep vein thrombosis—comorbidities and temporary provoking factors in a register‐based study of 1.48 million people
|
Glise Sandblad, Katarina
|
|
|
|
4 |
p.
|
artikel
|
| 150 |
Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions
|
Porres‐Aguilar, Mateo
|
|
|
|
4 |
p. 769
|
artikel
|
| 151 |
Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
|
Notten, Pascale
|
|
|
|
4 |
p. 594-603
|
artikel
|
| 152 |
Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study
|
Donners, Anouk A.M.T.
|
|
|
|
4 |
p.
|
artikel
|
| 153 |
Recognizing Excellence in Peer Review
|
|
|
|
|
4 |
p. 563
|
artikel
|
| 154 |
Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
|
Négrier, Claude
|
|
|
|
4 |
p.
|
artikel
|
| 155 |
Regulation of megakaryo/thrombopoiesis by endosomal toll-like receptor 7 and 8 activation of CD34+ cells in a viral infection model
|
Rodríguez, Camila Sofía
|
|
|
|
4 |
p.
|
artikel
|
| 156 |
Reliability of patient‐reported outcome measures: Hemorrhage, anticoagulant, antiplatelet medication use
|
Selvanayagam, Nicholyn
|
|
|
|
4 |
p.
|
artikel
|
| 157 |
Renal transplant and hemostasis: early postoperative changes in recipients and donors
|
Kohli, Ruchika
|
|
|
|
4 |
p.
|
artikel
|
| 158 |
Reproductive issues in women on direct oral anticoagulants
|
Beyer‐Westendorf, Jan
|
|
|
|
4 |
p.
|
artikel
|
| 159 |
Response to “Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis”
|
Patel, Jignesh P.
|
|
|
|
4 |
p.
|
artikel
|
| 160 |
Revisiting important issues in cancer and atrial fibrillation
|
Wang, Tzu-Fei
|
|
|
|
4 |
p.
|
artikel
|
| 161 |
RPTH year 6 article collection
|
Cushman, Mary
|
|
|
|
4 |
p.
|
artikel
|
| 162 |
Ruling out lupus anticoagulants with mixing test–specific cutoff assessment and the index of circulating anticoagulant
|
Kumano, Osamu
|
|
|
|
4 |
p. 695-703
|
artikel
|
| 163 |
Salivary tissue factor induces thrombin generation in a diurnal rhythm
|
van der Vorm, Lisa N.
|
|
|
|
4 |
p. 757-761
|
artikel
|
| 164 |
Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
|
Toorop, Myrthe M.A.
|
|
|
|
4 |
p. 586-593
|
artikel
|
| 165 |
Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study
|
Ma, Kim A.
|
|
|
|
4 |
p. 670-677
|
artikel
|
| 166 |
Seroprevalence to adeno‐associated virus type 6 in people with hemophilia B from a UK adult cohort
|
Boyce, Sara
|
|
|
|
4 |
p.
|
artikel
|
| 167 |
Sex‐specific aspects of venous thromboembolism: What is new and what is next?
|
Scheres, Luuk J.J.
|
|
|
|
4 |
p.
|
artikel
|
| 168 |
Spatial transcriptomics of murine bone marrow megakaryocytes at single-cell resolution
|
Tilburg, Julia
|
|
|
|
4 |
p.
|
artikel
|
| 169 |
Systematic review of fondaparinux for heparin‐induced thrombocytopenia: When there are no randomized controlled trials
|
Linkins, Lori‐Ann
|
|
|
|
4 |
p. 678-683
|
artikel
|
| 170 |
The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy
|
Singh, Pradeep K.
|
|
|
|
4 |
p.
|
artikel
|
| 171 |
The contact activation system as a potential therapeutic target in patients with COVID‐19
|
Shatzel, Joseph J.
|
|
|
|
4 |
p. 500-505
|
artikel
|
| 172 |
The experience of postpartum bleeding in women with inherited bleeding disorders
|
VanderMeulen, Heather
|
|
|
|
4 |
p. 733-740
|
artikel
|
| 173 |
The impact of PROS1 mutation position on thrombotic risk in protein S–deficient patients
|
Fenclova, Tereza
|
|
|
|
4 |
p.
|
artikel
|
| 174 |
The intracellular and plasma membrane pools of phosphatidylinositol-4-monophosphate control megakaryocyte maturation and proplatelet formation
|
Bura, Ana
|
|
|
|
4 |
p.
|
artikel
|
| 175 |
The Journey to a Successful Illustrated Review
|
Nersesian, Sarah
|
|
|
|
4 |
p.
|
artikel
|
| 176 |
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial
|
Blondon, Marc
|
|
|
|
4 |
p.
|
artikel
|
| 177 |
The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin
|
Sytema, Jelmer G.
|
|
|
|
4 |
p.
|
artikel
|
| 178 |
The risk of arterial thromboembolic events after cancer diagnosis
|
Navi, Babak B.
|
|
|
|
4 |
p. 639-651
|
artikel
|
| 179 |
Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability
|
Calzavarini, Sara
|
|
|
|
4 |
p. 758-768
|
artikel
|
| 180 |
Thrombolytic therapy in cardiac arrest caused by cardiac etiologies or presumed pulmonary embolism: An updated systematic review and meta‐analysis
|
Alshaya, Omar A.
|
|
|
|
4 |
p.
|
artikel
|
| 181 |
Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial
|
Ikesaka, Rick
|
|
|
|
4 |
p.
|
artikel
|
| 182 |
Thrombosis and hemostasis health in pregnancy: Registries from the International Society on Thrombosis and Haemostasis
|
Othman, Maha
|
|
|
|
4 |
p. 607-614
|
artikel
|
| 183 |
Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
|
Hosseinzadeh, Rezvan
|
|
|
|
4 |
p.
|
artikel
|
| 184 |
Thrombus composition and thrombolysis resistance in stroke
|
Ho-Tin-Noé, Benoit
|
|
|
|
4 |
p.
|
artikel
|
| 185 |
Tissue factor release following traumatic brain injury drives thrombin generation
|
Hubbard, W. Brad
|
|
|
|
4 |
p.
|
artikel
|
| 186 |
To escalate thromboprophylacic heparin intensity in COVID‐19 or not? That is still the question
|
Bikdeli, Behnood
|
|
|
|
4 |
p.
|
artikel
|
| 187 |
Using heparin molecules to manage COVID‐2019
|
Liu, Jian
|
|
|
|
4 |
p. 518-523
|
artikel
|
| 188 |
Vaccine‐induced prothrombotic immune thrombocytopenia without thrombosis may not require immune modulatory therapy: A case report
|
Lai, Chieh Min Benjamin
|
|
|
|
4 |
p.
|
artikel
|
| 189 |
Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes
|
Ageno, Walter
|
|
|
|
4 |
p.
|
artikel
|
| 190 |
Venous thrombosis in evacuees during war: Will the experience of our ancestors be put to good use?
|
Sueta, Daisuke
|
|
|
|
4 |
p.
|
artikel
|
| 191 |
von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
|
Warlo, Ellen M.K.
|
|
|
|
4 |
p.
|
artikel
|
| 192 |
Von Willebrand factor and the thrombophilia of severe COVID-19: in situ evidence from autopsies
|
van den Berg, Jana
|
|
|
|
4 |
p.
|
artikel
|
| 193 |
Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
|
Wanat, Matthew A.
|
|
|
|
4 |
p. 674-683
|
artikel
|
| 194 |
#WomenInMedicine: Progress in gender equity at Research and Practice in Thrombosis and Haemostasis
|
Cushman, Mary
|
|
|
|
4 |
p. 560-562
|
artikel
|
Tijdschrift beschrijving